The Virogen CMV Antibody Test is a simple and rapid latex agglutination assay for the detection of cytomegalovirus antibody in human serum and plasma. Evaluation of this assay with respect to enzyme immunoassay yielded a sensitivity of 98% with a specificity of 100%. In comparison to CMVScan, the Virogen CMV Antibody Test had a sensitivity of 98.4% and a specificity of 100%.
The majority of cytomegalovirus (CMV) infections are asymptomatic, but there is a risk of serious complications when CMV infections occur congenitally or in immunocompromised individuals (5) (6) (7) (8) (9) . Detection of serum antibody can help in identifying those individuals with prior CMV exposure and may aid in confirming acute CMV infection (P. Klevjer-Anderson, Clin. Microbiol. Newsl. 9:36-38, 1987). Moreover, absence of CMV antibody by serological testing can identify those individuals at risk for CMV infection. This is extremely important in immunocompromised patients who may be receiving blood products and, based on CMV seronegativity, should be given seronegative CMV blood products (3, 4) .
CMV antibodies in patient sera can be measured by a variety of serological immunoassays. These include complement fixation, solid-phase radioimmunoassay, latex agglutination assay (LA), indirect hemagglutination assay, indirect fluorescent-antibody test, anti-complement fluorescent-antibody test, neutralization, and enzyme immunoassay (EIA) (1, 3, 4, 6) . We report here the use of a simple and rapid LA for the detection of CMV antibody in human serum or plasma.
A total of 427 serum specimens from 303 potential marrow transplant recipients and 124 random samples from adult blood donors were used in the evaluation of the Virogen CMV Antibody Test (Wampole Laboratories, Cranbury, N.J.), an LA. All 427 serum specimens were also assayed with CMVScan LA (BBL Microbiology Systems, Cockeysville, Md.), and 360 of the samples were available for testing by EIA (CMV Stat; Whittaker M.A. Bioproducts, Walkersville, Md.). The Virogen test was performed per the package insert as follows. Sera were screened undiluted by mixing 0.025 ml of serum sample with one drop of Virogen CMV latex on a black disposable card slide. The card slide was rotated at 100 rpm for 10 min, and the agglutination patterns were immediately examined under an obliquely projected light and compared with the negative control wells for a positive or negative reaction. In the paired-serum study, 0.025 ml of serum was mixed with 0.025 ml of sample diluent (provided in Virogen kit) and serial twofold dilutions of each serum sample were performed on the card slide to a 1:1,024 dilution. All dilutions were tested to determine the endpoint titer by mixing 0.025 ml of serum dilution with one drop of Virogen CMV latex. * Corresponding author.
Agglutination was defined as follows. A nonreactive or negative result was indicated by a fine granular background or a cloudy background with absence of agglutination. A reactive or positive result was indicated by distinct large clumps against a clear or slightly cloudy background or small but definite clumps against a cloudy background. The CMVScan test was performed in accordance with the procedures described in the package insert and as previously described (1, 2) . Serum samples were screened undiluted, and endpoint titrations were performed by serially diluting samples on the disposable card slide.
In a 96-well microdilution format, the EIA was performed as specified by the manufacturer. Sera were tested at a 1:21 dilution in wells containing CMV antigen. There was no antigen control well in the CMV Stat format. After incubation with the enzyme substrate, the sample wells were read at a 550-nm wavelength on a microplate autoreader EL310 (BIO-TEK Instruments; provided by Whittaker M. A. Bioproducts). Samples that were antibody positive by EIA were those with absorbance values greater than or equal to the value obtained with the low-positive standard provided in the EIA kit.
Serum and plasma samples containing sodium heparin, EDTA, or sodium citrate anticoagulants were drawn from each of eight donors. All samples were screened by Virogen for CMV antibody as described above.
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